NCT06754345
- Conditions
- Disease, Neoplasms, PD-L1, +3 more
- Locations
-
- The First Affiliated Hospital of Xiamen University Xiamen, Fujian, China
Clinical trial condition
PD-L1
Explore clinical trials studying PD-L1. Study availability and eligibility vary by location and protocol.
8 public trials
4 recruiting studies
PD-L1 trial results
NCT07312422
- Conditions
- Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +10 more
- Locations
-
- Zhejiang Provincial People's Hospital Hangzhou, Zhejiang, China
- Conditions
- Cancer, Immune Checkpoint Therapy, Immunotherapy, +3 more
- Locations
-
- Eastern Connecticut Hematology and Oncology Norwich, Connecticut, United States
- Cancer Center of Middle Georgia Dublin, Georgia, United States
- Carolina Blood and Cancer Care Associates Rock Hill, South Carolina, United States
NCT05397769
- Conditions
- Envafolimab, Induction Chemotherapy, Locally Advanced Nasopharyngeal Carcinoma, +1 more
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
Not Yet Recruiting
PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor
NCT07442292
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +23 more
- Locations
-
Not specified
Not Yet Recruiting
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
NCT06699498
- Conditions
- Anlotinib, Carcinoma, Carcinoma, Squamous Cell, +9 more
- Locations
-
- The First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu, China
NCT04247217
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +9 more
- Locations
-
- Maastro Maastricht, Netherlands
Active, Not Recruiting
PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment
NCT04634058
- Conditions
- Adenocarcinoma, CTLA4, Carcinoma, +6 more
- Locations
-
- Zhongshan hospital Shanghai, China